The report is based on two surveys conducted in March 2026: a Censuswide survey of 250 U.S. C-level executives at large, multi-site health systems with self-funded plans, and a Pollfish survey of 352 ...
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management ...
TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announce that we have been awarded the contract for a second installation ...
First multinational initiative dedicated to long-term HIFU outcomes in prostate cancer and BPH aims to help close the evidence gap in incision-free prostate care CHARLOTTE, N.C., May 14, 2026 (GLOBE ...
CJ Biomaterials, Inc., a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, has announced the commercial availability of PHACT™ CB0504A, a ...
Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication o ...
Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, ...
First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized treatment ...
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early ...
ApolloMD has been selected by Modern Healthcare 2026 Best Places to Work in Healthcare, recognizing healthcare organizations that foster strong workplace culture, support career development, and ...
MOA: Evidence across multiple, independent measures, including serum proteomics (17 analytes), whole-blood RNA-sequencing and flow cytometry suggest disease-modifying benefits, including immune ...
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results